TScan Therapeutics (TCRX) Expected to Announce Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) is anticipated to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect TScan Therapeutics to post earnings of ($0.35) per share and revenue of $1.98 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28). The business had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $1.31 million. TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Stock Down 0.4%

TCRX traded down $0.01 during trading hours on Tuesday, reaching $1.24. 470,070 shares of the stock traded hands, compared to its average volume of 491,643. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The company has a market cap of $70.09 million, a price-to-earnings ratio of -1.13 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06. The firm’s fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $1.73.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently bought and sold shares of TCRX. JPMorgan Chase & Co. lifted its position in shares of TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock worth $417,000 after purchasing an additional 22,642 shares in the last quarter. Bank of America Corp DE increased its position in TScan Therapeutics by 28.0% during the second quarter. Bank of America Corp DE now owns 217,967 shares of the company’s stock worth $316,000 after buying an additional 47,617 shares during the last quarter. Jane Street Group LLC bought a new stake in TScan Therapeutics in the second quarter valued at approximately $309,000. Goldman Sachs Group Inc. lifted its position in shares of TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its holdings in shares of TScan Therapeutics by 35.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company’s stock worth $223,000 after acquiring an additional 40,400 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TCRX shares. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. BTIG Research downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday. Needham & Company LLC cut their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Wall Street Zen upgraded shares of TScan Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, TScan Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $7.20.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.